Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled

Annovis reached full enrollment in its pivotal Phase 3 buntanetap trial, enrolling 850 pTau217‑confirmed early AD patients across 83 U.S. sites.

Key Highlights:

• Phase 3 trial (NCT06709014) fully enrolled 850 patients with pTau217‑confirmed early Alzheimer’s disease.
• Dual readouts planned: 6‑month symptomatic top‑line data in Q1 2027 and 18‑month disease‑modifying data in Q1 2028.
• Trial is randomized, placebo‑controlled, double‑blind; primary endpoints are ADAS‑Cog13 and ADCS‑iADL.
• Annovis is preparing separate NDA submissions to FDA following each respective data readout.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.